Vaccination against a new coronavirus infection in patients with cancer

   With a new coronavirus infection caused by SARS-CoV-2, cancer patients with malignant neoplasms are the most vulnerable group of people. Cancer patients are at a higher risk of severe COVID-19, and for them the vaccination of a new coronavirus infection is crucial. For cancer patients, the study of the effectiveness and safety of vaccination of a new coronavirus infection in large groups was not carried out. The available recommendations are based on data obtained on the safety and effectiveness of vaccines against SARS-CoV-2 in the general population, as well as on the study of the effectiveness and safety of other vaccines in cancer patients. It is believed that the potential benefits of vaccines against a new coronavirus infection outweigh the risks and therefore vaccination in these patients is recommended by cancer communities. All guidelines for the immunoprophylaxis of a new coronavirus infection in patients with oncopathology are temporary and will change as new data become available. It is necessary to personalize vaccination against COVID-19 in cancer patients. The problem of vaccination against SARS-CoV-2 in cancer patients requires in-depth study, conducting clinical trials from the standpoint of evidence-based medicine and evaluation on a sufficiently large number of patients.

1. Desai A., Gupta R., Advani S., Ouellette L., Kuderer N. M., Lyman G. H., Li A. Mortality in hospitalized patients with cancer and coronavirus disease 2019 : A systematic review and meta-analysis of cohort studies // Cancer. 2021. Vol. 127, no. 9. P. 1459–1468. doi: 10.1002/cncr.33386.

2. Leung W. F., Chorlton S., Tyson J., Al-Rawahi G. N., Jassem A. N., Prystajecky N., Masud S., Deans G. D., Chapman M. G., Mirzanejad Y., Murray M. C. M., Wong P. H. P. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations : a case report // International Journal of Infectious Diseases. 2022 Vol. 114, P. 178–182. doi: 10.1016/j.ijid.2021.10.045.

3. Kuderer N. M., Choueiri T. K., Shah D. P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19) : a cohort study // Lancet. 2020. Vol. 395, no. 10241. P. 1907–1918. doi: 10.1016/S0140-6736(20)31187-9.

4. Kostinov M. P. Immunopathogenic properties of sars-cov-2 as a basis for the choice of pathogenetic therapy. Immunologiya. 2020; 41 (1): 83–91. doi: 10.33029/0206-4952-2020-41-1-83-91. (In Russ.).

5. Kostinov M. P. Fundamentals of immunorehabilitation for a new coronavirus infection (COVID-19). Manual for doctors. Moscow: MDV Group; 2020. 112 р. (In Russ.).

6. ESMO statements for vaccination against COVID-19 in patients with cancer. URL: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination.

7. Shumilov E., Hoffknecht P., Koch R., Peceny R., Voigt S., Schmidt N., Peeck M., Bacher U., Scheithauer S., Trümper L., Lenz G., Kerkhoff A., Bleckmann A. Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2 : Retrospective Analysis in Three German Cancer Centers // Cancers (Basel). 2021. Vol. 13, no. 12. P. 2917. doi: 10.3390/cancers13122917.

8. Priority vaccination for respiratory infections during and after the SARS-CoV-2 pandemic. Manual for doctors. Ed. M. P. Kostinov, A. G. Chuchalin. Moscow: MDV Group; 2020. 32 p. (In Russ.).

9. Kostinov M. P. Svitich O. A., Markelova E. V. Potential immunoprophylaxis of COVID-19 in high-risk groups. Temporary allowance for doctors. Moscow: MDV Group; 2020. 64 p. (In Russ.).

10. Dooling K., McClung N., Chamberland M., Marin M., Wallace M., Bell B. P., Lee G. M., Talbot H. K., Romero J. R., Oliver S. E. The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – United States, 2020. // MMWR. Morbidity and mortality weekly report. 2020. Vol. 69, no. 49. P. 1857–1859. doi: 10.15585/mmwr.mm6949e1.

11. Corti C., Crimini E., Tarantino P., Pravettoni G., Eggermont A. M. M., Delaloge S., Curigliano G. SARS-CoV-2 vaccines for cancer patients : a call to action // European Journal of Cancer. 2021. Vol. 148. P. 316–327. doi: 10.1016/j.ejca.2021.01.046.

12. NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies. URL: https://multiplemyelomahub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies

13. SITC Statement on SARS-CoV-2 Vaccination and Cancer Immunotherapy. URL: https://www.sitcancer.org/aboutsitc/press-releases/2020/sitc-statement-sars-cov-2-vaccination-cancer-immunotherapy

14. COVID-19 Clinical Guidance. URL: https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/Clinical-Guidance.

15. MSK COVID-19 vaccine interim guidelines for cancer patients. URL: https://www.asco.org/sites/new-www.asco.org/files/content-files/covid-19/2021-MSK-COVID19-VACCINE-GUIDELINES.pdf.

16. Becker A. S., Perez-Johnston R., Chikarmane S. A., Chen M. M., El Homsi M., Feigin K. N., Gallagher K. M., Hanna E. Y., Hicks M., Ilica A. T., Mayer E. L., Shinagare A. B., Yeh R., Mayerhoefer M. E., Hricak H., Vargas H. A. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging : Radiology Scientific Expert Panel // Radiology. 2021. Vol. 300, no. 2. P. E323–E327. doi: 10.1148/radiol.2021210436.

17. Goshen-Lago T., Waldhorn I., Holland R., Szwarcwort-Cohen M., Reiner-Benaim A., Shachor-Meyouhas Y., Hussein K., Fahoum L., Baruch M., Peer A., Reiter Y., Almog R., Halberthal M., Ben-Aharon I. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer // JAMA oncology. 2021. Vol. 7, no. 10. P. 1507–1513. doi: 10.1001/jamaoncol.2021.2675.

18. Avivi I., Balaban R., Shragai T., Sheffer G., Morales M., Aharon A., Lowenton-Spier N., Trestman S., Perry C., Benyamini N., Mittelman M., Tabib Y., Bar Lev T., Zavaro M., Herishanu Y., Luttwak E., Cohen Y. C. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma // British Journal of Haematology. 2021. Vol. 195, no. 2. P. 186–193. doi: 10.1111/bjh.17608.

19. Chevallier P., Coste-Burel M., Le Bourgeois A., Peterlin P., Garnier A., Béné M. C., Imbert B. M., Drumel T., Le Gouill S., Moreau P., Mahe B., Dubruille V., Blin N., Lok A., Touzeau C., Gastinne T., Jullien M., Vanthygem S., Guillaume T. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients // EJHaem. 2021. Vol. 2, no. 3. P. 520–524. doi: 10.1002/jha2.242.

20. COVID-19 Treatment Guidelines Guidelines Development. URL: www.covid19treatmentguidelines.nih.gov Last Updated: April 29, 2022.

21. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. On 2022. URL: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#:~:text=Use%20of%20COVID%2D19%20Vaccines%20in%20the%20United%20States&text=People%20ages%206%20years%20and,additional%20bivalent%20mRNA%20vaccine%20dose

22. Interim guidelines “Procedure for vaccination of the adult population against COVID-19” ot 24. Krause P. R., Fleming T. R., Peto R., Longini I. M., Figueroa J. P., Sterne J. A. C., Cravioto A., Rees H., Higgins J. P. T., Boutron I., Pan H., Gruber M. F., Arora N., Kazi F., Gaspar R., Swaminathan S., Ryan M. J., Henao-Restrepo A. M. Considerations in boosting COVID-19 vaccine immune responses // Lancet. Vol. 398, no. 10308, P. 1377–1380. doi: 10.1016/S0140-6736(21)02046-8.

23. Temporary guidelines. The procedure for vaccination against a new coronavirus infection (COVID-19). Moscow: Ministry of Health of the Russian Federation; 2022. 80 p. (In Russ.).

24. Krause P. R., Fleming T. R., Peto R., Longini I. M., Figueroa J. P., Sterne J. A. C., Cravioto A., Rees H., Higgins J. P. T., Boutron I., Pan H., Gruber M. F., Arora N., Kazi F., Gaspar R., Swaminathan S., Ryan M. J., Henao-Restrepo A. M. Considerations in boosting COVID-19 vaccine immune responses. Lancet; 398 (10308): 1377–1380. doi: 10.1016/S0140-6736(21)02046-8.

25. Guidelines for Clinical Immunology in Respiratory Medicine / Ed. M. P. Kostinov, A. G. Chuchalin. Moscow: MDV Group; 2018. 304 p. (In Russ.).